260 related articles for article (PubMed ID: 38672463)
1. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in Colorectal Carcinoma Cells.
Jacksi M; Schad E; Tantos A
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
[TBL] [Abstract][Full Text] [Related]
2. Absence of Scaffold Protein Tks4 Disrupts Several Signaling Pathways in Colon Cancer Cells.
Jacksi M; Schad E; Buday L; Tantos A
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674824
[TBL] [Abstract][Full Text] [Related]
3. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
[TBL] [Abstract][Full Text] [Related]
4. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
5. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
6. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
[TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
9. Absence of the Tks4 Scaffold Protein Induces Epithelial-Mesenchymal Transition-Like Changes in Human Colon Cancer Cells.
Szeder B; Tárnoki-Zách J; Lakatos D; Vas V; Kudlik G; Merő B; Koprivanacz K; Bányai L; Hámori L; Róna G; Czirók A; Füredi A; Buday AL
Cells; 2019 Oct; 8(11):. PubMed ID: 31671862
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
11. A Novel Cell-Based Model for a Rare Disease: The Tks4-KO Human Embryonic Stem Cell Line as a Frank-Ter Haar Syndrome Model System.
László L; Maczelka H; Takács T; Kurilla A; Tilajka Á; Buday L; Vas V; Apáti Á
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955935
[TBL] [Abstract][Full Text] [Related]
12. EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3.
Luo H; Jiang Y; Ma S; Chang H; Yi C; Cao H; Gao Y; Guo H; Hou J; Yan J; Sheng Y; Ren X
Biochem Biophys Res Commun; 2016 Oct; 479(2):253-259. PubMed ID: 27638307
[TBL] [Abstract][Full Text] [Related]
13. SUMOylation of E2F1 Regulates Expression of EZH2.
Du L; Fakih MG; Rosen ST; Chen Y
Cancer Res; 2020 Oct; 80(19):4212-4223. PubMed ID: 32816857
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis.
Zhang Q; Dong P; Liu X; Sakuragi N; Guo SW
Sci Rep; 2017 Jul; 7(1):6804. PubMed ID: 28754964
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
[TBL] [Abstract][Full Text] [Related]
16. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
17. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
18. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
19. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
Shi Y; Xu L; Tao M; Fang L; Lu J; Gu H; Ma S; Lin T; Wang Y; Bao W; Qiu A; Zhuang S; Liu N
Am J Physiol Renal Physiol; 2019 Mar; 316(3):F488-F505. PubMed ID: 30566000
[TBL] [Abstract][Full Text] [Related]
20. The Effect of
Özel M; Kilic E; Baskol M; Akalın H; Baskol G
Cell Reprogram; 2021 Apr; 23(2):139-148. PubMed ID: 33861639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
